[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335394-105":59,"doc-detail-335394-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","combining-data-driven-and-structure-based-approaches-in-designing-dual-parp1-brd4-inhibitors-for-breast-cancer-treatment","Combining Data-Driven and Structure-Based Approaches in Designing Dual PARP1-BRD4 Inhibitors for Breast Cancer Treatment","","Poly(ADP-ribose) polymerase 1 (PARP1) inhibitors have transformed cancer therapy for tumors with DNA-repairing deficiencies through synthetic lethality. Motivated by polypharmacology, evidence shows that jointly perturbing bromodomain-containing protein 4 (BRD4) and PARP1 produces a significantly synergistic enhancement in cancer-cell death. A novel cheminformatics pipeline integrating structure-based design was developed to enable dual PARP1-BRD4 inhibitor discovery. The method prioritizes merged amide-containing ring systems and selects phenanthridin-6(5H)-one as a key starting point. Rational synthesis yielded molecules including HF4 with low micromolar inhibition and strong BRD4 BD1 activity (IC50 204 nM). HF4 also showed potent antiproliferative effects by arresting the cell cycle and impairing DNA damage repair in breast cancer cells with or without BRCA gene deficiency. The approach supports systematic lead-like design and can extend to PARP1 and other targets.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/combining-data-driven-and-structure-based-approaches-in-designing-dual-parp1-brd4-inhibitors-for-breast-cancer-treatment/335394/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/combining-data-driven-and-structure-based-approaches-in-designing-dual-parp1-brd4-inhibitors-for-breast-cancer-treatment/335394.png","ImageObject",300,407,{"name":92,"@type":93},"River Wang","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What therapeutic rationale supports designing dual PARP1-BRD4 inhibitors?","Question",{"text":112,"@type":113},"The document explains that synthetic lethality makes PARP1 inhibition effective for tumors with DNA-repair deficiencies, and that simultaneously perturbing BRD4 and PARP1 can produce synergistic cancer-cell death under a polypharmacology concept.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does the developed cheminformatics approach guide inhibitor design?",{"text":117,"@type":113},"Instead of directly linking pharmacophores, it first identifies merged pharmacophores from amide-containing ring systems and then prioritizes phenanthridin-6(5H)-one to support structure-based rational design.",{"name":119,"@type":110,"acceptedAnswer":120},"What performance did compound HF4 achieve against PARP1 and BRD4?",{"text":121,"@type":113},"HF4 exhibited low micromolar inhibitory activity against both targets, with particularly strong BRD4 BD1 inhibition (IC50 204 nM).",{"name":123,"@type":110,"acceptedAnswer":124},"How did HF4 affect breast cancer cells in functional experiments?",{"text":125,"@type":113},"HF4 produced potent antiproliferative effects in breast cancer cell lines with and without BRCA gene deficiency by arresting cell cycle progression and impeding DNA damage repair.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},335394,1790158875,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":4},1099514067438,"https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542","This article is licensed under CC-BY 4.0   \n[pubs.acs.org/jcim](pubs.acs.org/jcim)  Article   \nCombining Data-Driven and Structure-Based Approaches in  \nDesigning Dual PARP1-BRD4 Inhibitors for Breast Cancer Treatment  \nBo Feng, Hui Yu, Xu Dong, Alejandro Díaz-Holguín, Albert A. Antolin, and Huabin Hu*  \n Cite This: J. Chem. Inf. Model. 2024, 64, 7725−7742  \nRead Online  \n\n|  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- |\n| ACCESS   | Metrics & More |  |  Article Recommendations |  | *sı Supporting Information |\n\nABSTRACT: Poly(ADP-ribose) polymerase 1 (PARP1) inhibitors have revolutionized the treatment of many cancers with DNA-repairing deficiencies via synthetic lethality. Advocated by the polypharmacology concept, recent evidence discovered that a significantly synergistic effect in increasing the death of cancer cells was observed by simultaneously perturbating the enzymatic activities of bromodomaincontaining protein 4 (BRD4) and PARP1 . Here, we developed a novel cheminformatics approach combined with a structure-based method aiming to facilitate the design of dual PARP1-BRD4 inhibitors. Instead of linking pharmacophores, the developed approach first identified merged pharmacophores (a pool of amide-containing ring systems), from which phenanthridin-6(5H)-one was further prioritized. Based on this starting point, several small molecules were rationally designed, among which HF4 exhibited low micromolar inhibitory activity against BRD4 and PARP1, particularly exhibiting strong inhibition of BRD4 BD1 with an IC50 value of 204 nM. Furthermore, it demonstrated potent antiproliferative effects against breast cancer gene-deficient and proficient breast cancer cell lines by arresting cell cycle progression and impeding DNA damage repair. Collectively, our systematic efforts to design lead-like molecules have the potential to open doors for the exploration of dual PARP1-BRD4 inhibitors as a promising avenue for breast cancer treatment. Furthermore, the developed approach can be extended to systematically design inhibitors targeting PARP1 and other related targets.  \n■ INTRODUCTION  \nConventional drug discovery mainly focuses on designing chemical entities that are highly selective and potent for their primary target. Such a single-target therapeutic tactic strongly adheres to a direct cause-effect relationship linking the phenotype of disease to the loss of function of a particular protein. 1−3 However, diseases􀀁especially multifactorial disorders􀀁are frequently perceived as aberrant signaling transductions in a physiological network pathway involving multiple targets.4 Accordingly, based on the network pharmacology concept,5 multitarget profiles of a compound are gaining momentum in drug discovery pipeline in recent decades and represent an effective strategy for the treatment of complex and multifactorial diseases including oncology and neurodegenerative diseases.6−9  \nPoly(ADP-ribose) polymerase 1 (PARP1) has been confirmed as a therapeutical target in oncology whose inhibitors have been successfully approved as a monotherapeutic agent in clinics for the treatment of patients harboring breast cancer gene (BRCA) mutation via the synthetic lethality mechanism. 10, 11 Thus far, the U.S. Food and Drug Administration (FDA) has authorized four PARP1 inhibitors (olaparib, rucaparib, talazoparib, and niraparib) for the treatment of diverse tumor types, such as ovarian cancer and HER2-negative breast cancer.12 From a chemical viewpoint, all approved PARP1 inhibitors and PJ34 (a potent and non-  \nselective PARP inhibitor) 13 have a common feature: the presence of a benzamide group, which can be either a primary or secondary amide, as shown in Figure 1A. This structural element is strategically incorporated into various scaffolds to mimic the nicotinamide moiety of the PARP1 substrate NAD+ . It possesses the ability to form advantageous hydrogen bonding networks with crucial amino acid residues (Gly863 and Ser904) and participa","cbCailhXZqxpMTM1","https://ap.wps.com/l/cbCailhXZqxpMTM1","pdf",9579185,18,"English","# Abstract\n# Introduction\n## PARP1 as a synthetic lethal target\n## Approved PARP1 inhibitors and shared benzamide features\n## BRD4 as an epigenetic regulator\n## Binding modes and dual-target inhibitor context","[{\"question\":\"What therapeutic rationale supports designing dual PARP1-BRD4 inhibitors?\",\"answer\":\"The document explains that synthetic lethality makes PARP1 inhibition effective for tumors with DNA-repair deficiencies, and that simultaneously perturbing BRD4 and PARP1 can produce synergistic cancer-cell death under a polypharmacology concept.\"},{\"question\":\"How does the developed cheminformatics approach guide inhibitor design?\",\"answer\":\"Instead of directly linking pharmacophores, it first identifies merged pharmacophores from amide-containing ring systems and then prioritizes phenanthridin-6(5H)-one to support structure-based rational design.\"},{\"question\":\"What performance did compound HF4 achieve against PARP1 and BRD4?\",\"answer\":\"HF4 exhibited low micromolar inhibitory activity against both targets, with particularly strong BRD4 BD1 inhibition (IC50 204 nM).\"},{\"question\":\"How did HF4 affect breast cancer cells in functional experiments?\",\"answer\":\"HF4 produced potent antiproliferative effects in breast cancer cell lines with and without BRCA gene deficiency by arresting cell cycle progression and impeding DNA damage repair.\"}]","Combining Data-Driven and Structure-Based Approaches in Designing Dual PARP1-BRD4 Inhibitors for Breast Cancer Treatment | PDF",1790010808,45]